Summary
PROLONG-ANG3 is a phase 2 randomised controlled trial investigating solbinsiran, a novel GalNAc-conjugated siRNA therapeutic targeting ANGPTL3, as a treatment for mixed dyslipidaemia in adults. The trial assessed both the efficacy in modulating lipid metabolism and the durability of treatment effects over time, as suggested by the trial name and design. Published in The Lancet in 2025, the findings contribute to evidence on RNA-based therapeutics for cardiovascular risk reduction, though this record does not indicate specific nutrient density or farming systems relevance.
UK applicability
If approved, solbinsiran could offer a novel therapeutic option for UK patients with dyslipidaemia resistant to conventional statin therapy; however, the findings are primarily of clinical and pharmaceutical relevance rather than directly applicable to agricultural or food systems policy in the United Kingdom.
Key measures
Serum lipid concentrations (as suggested by the dyslipidaemia indication), ANGPTL3 suppression, lipid ratios, safety and adverse event profiles, durability of therapeutic effect
Outcomes reported
The study evaluated the durability and efficacy of solbinsiran (a GalNAc-conjugated siRNA targeting ANGPTL3) in reducing lipid levels and cardiovascular risk markers in adults with mixed dyslipidaemia. Primary outcomes appear to include lipid panel measurements and safety/tolerability assessments over an extended follow-up period.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.